Taipei, Taiwan

Yung-Shun Wen

This inventor holds 5 USPTO granted patents and 2 published patent applications and 4 EPO patents. Top assignee: Alar Pharmaceuticals, Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yung-Shun Wen. Retrieved from https://idiyas.com/inventor/yung-shun-wen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Taipei, TW (2020)
  • Taichung, TW (2022 - 2024)

Company Filing History:


Years Active: 2020-2026

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Yung-Shun Wen: Innovator in Pharmaceutical Formulations

Introduction

Yung-Shun Wen is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of long-acting injectable medications. With a total of 5 patents to his name, Wen's work focuses on innovative solutions for treating opioid dependence, pain, and depression.

Latest Patents

Wen's latest patents include groundbreaking formulations such as long-acting injectable formulations and crystalline forms of buprenorphine derivatives. This disclosure relates to crystalline forms of 3-acyl-buprenorphine derivatives and sustained release injectable pharmaceutical compositions. These compositions are designed for the treatment of opioid dependence, pain, or depression, and include an aqueous suspension of crystalline 3-acyl-buprenorphine or a pharmaceutically acceptable salt thereof. Notably, the composition does not include an organic solvent, a polylactide polymer, a polyglycolide polymer, or a copolymer of polylactide and polyglycolide. Additionally, the disclosure encompasses 3-acyl-buprenorphine or a pharmaceutically acceptable salt prepared in a controlled release matrix, which includes poly(lactide-co-glycolide), sucrose acetoisobutyrate, lecithin, diolein, and combinations thereof. Another significant patent is the naltrexone injectable sustained release formulation, which includes 3-acyl-naltrexone or a pharmaceutically acceptable salt, a biocompatible organic solvent, and optionally a biocompatible polymeric material. This formulation provides a sustained release profile after a single injection, demonstrating efficacy in treating opioid use disorder or alcoholism.

Career Highlights

Yung-Shun Wen is currently associated with Alar Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing the development of effective treatments for complex medical conditions.

Collaborations

Wen collaborates with notable colleagues such as Tong-Ho Lin and Jui-Wei Liang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Yung-Shun Wen's contributions to pharmaceutical formulations highlight his role as a key innovator in the field. His patents reflect a commitment to developing effective treatments for opioid

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…